Join TechBio Companies Driving Patient Impact

Sponsored by Alix Ventures

Post a job // Join our newsletter
BIOS Community
BIOS Community

Scientist or Senior Scientist, Therapeutics



Redwood City, CA, USA
Posted on Friday, May 31, 2024

About Earli

Earli exists to make cancer a benign experience. Earli does that by turning cancers against themselves: genetically forcing them to reveal themselves early, and then kill themselves – precisely and clearly distinguishable from benign lesions at early stages. Based on original technology from Stanford’s renowned Gambhir lab, Earli designs genetic constructs that are injected intravenously that turn cancer cells against themselves. These programmable synthetic promoter-reporter sequences “flip on” like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope “docking station” for imaging agents, or a cytokine for immune system activation against the tumor. Thus, Earli’s platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence.

Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers.

Earli has raised $82m in three rounds from investors including Andreessen Horowitz, Khosla Ventures, Emerson Collective, Stanford, Perceptive Advisors, Casdin Capital, Marc Benioff, Sands Capital, Breyer Capital, Tailwinds (American-Korean) etc.

Its Scientific Advisory Board includes Jim Allison (Nobel Laureate, Immuno Oncology), Bob Langer (MIT, co-founder Moderna), Phil Greenberg (Hutch, co-founder Juno), Pam Sharma (MD Anderson), Charlie Rudin (Sloan Kettering), Alan Ashworth (UCSF Cancer Center).

Who You Are

  • You share our same sense of dedication, scientific passion and entrepreneurial spirit
  • You work well in a fast-paced and extremely focused startup environment
  • You are not only smart, but clever and constantly think outside the box
  • You are able to make logical decisions in an instant when there is little time to evaluate
  • You are a natural communicator and relationship builder
  • You stay calm under high pressure and stress
  • You have the ability to multi-task in a serious way, with an extreme attention to detail
  • You become a representative of the core DNA of the company through who you are

The Position

Earli, Inc. is currently seeking a highly motivated and committed Scientist / Senior Scientist for our Therapeutics team with a background in immunology. This position will report to the Head of Therapeutics.

Your Primary Responsibilities:

Earli’s platform technology uses cancer-activated gene expression to usurp the dysregulated pathways that lead to malignancy. As a scientist or senior scientist you will be leveraging this platform for the creation of novel therapeutic approaches to treat cancer. Within this context, you will:

Utilize a wide variety of cellular immunology and molecular immunology techniques to contribute to the identification and validation of therapeutic targets

  • Design and execute strategies in preclinical models for the development of novel gene therapy and/or cell therapy agents for the treatment cancer
  • Use immunology techniques including cytokine analysis, functional assays, imaging, and cell biology in order to ascertain mechanism of action or immunotoxicity
  • Work with other team members to generate appropriate efficacy and safety data packages for the advancement of clinical candidates for regulatory submission.
  • Document results and communicate findings to internal teams and to external partners

Your Required Experience, Knowledge and Skills:

  • PhD in immunology, cell biology, or a related discipline.
  • Minimum of 4+ years of industry experience developing gene therapy or cell therapy based approaches for the treatment of cancer
  • Have an exceptionally strong background in immunology, cancer genetics, or cellular mechanisms of oncogenesis including a proficient understanding of the innate and adaptive immune response to cancer
  • Must have technical expertise with in vitro cellular & molecular immunology assays
  • Must be proficient with flow cytometry acquisition and analysis
  • Hands-on molecular biology experience that includes DNA and RNA isolation, various cloning techniques & strategies, PCR, qPCR, and standard biochemical assays
  • Previous experience with nucleic acid based expression approaches including viral and non-viral transductions methods as well as engineering cell lines for various readouts and functions is preferred
  • Must be able to think outside of the box
  • Ability to integrate and collaborate into a high achieving team environment
  • Ability to handle multiple projects simultaneously and meet aggressive project timelines
  • Exceptional verbal communication and scientific writing skills are required
  • Desire to continue to continue in a laboratory focused role

If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.

We look forward to hearing from you!